ButcherNJ, FungWL, FitzpatrickL, GunaA, AndradeDM, LangAE, et al.: Response to clozapine in a clinically identifiable subtype of schizophrenia. Br J Psychiatry, 206:484–491, 2015.
2.
GothelfD, FeinsteinC, ThompsonT, PennimanEGL, Van StoneE, KwonH, EliezS, ReissAL: Risk factors for the emergence of psychotic disorders in adolescents with 22q11.2 deletion syndrome. Am J Psychiatry, 164:663–669, 2007.
3.
RoukasD, SmyrnisN, StefanisN, HatzimanolisI, SoldatosC: Schizophrenia and Di George syndrome. Report of a case. Ann Gen Psychiatry, 5(Suppl 1):S286, 2006.
4.
SchneiderC, PapachristouE, WiberleyT, GasseC, DimaD, MacCabeJH, et al.: Clozapine use in childhood and adolescent schizophrenia: A nationwide population-based study. Eur Neuropsychopharmacol, 25:857–863, 2015.
5.
WilliamsAM, ParkSH: Seizure associated with clozapine: Incidence, etiology and management. CNS Drugs, 29:101–111, 2015.
